Consequently, precise methods for differentiating normal and tumor-associated EVs (TAEs) are required. Methods: This study used quantifiable antibody-DNA conjugate-assisted quantitative methods ...

SMi is proud to present their 6th annual Antibodies and Antibody Drug Conjugates conference, being held at the Copthorne Tara Hotel, London, UK on the 9 th – 10 th April 2018. With an every ...

Antibody-drug conjugates (ADCs) are transforming the treatment landscape in metastatic bladder ... tolerated and resulted in improved tumor control compared to either agent alone in vivo. We also ...

With a strong track record of innovation and quality, GBI supports the development of complex biologics, including monoclonal antibodies, conjugates, and other therapeutic modalities. For more ...

With a strong track record of innovation and quality, GBI supports the development of complex biologics, including monoclonal antibodies, conjugates, and other therapeutic modalities. For more ...

SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive ...

Oligonucleotide therapies are among the most promising biological therapeutics. They target disease at a different stage of ...

OBI-992 is an antibody–drug conjugate (ADC) derived from a novel TROP2-targeted antibody linked to the topoisomerase 1 (TOP1) inhibitor exatecan via an enzyme-cleavable hydrophilic linker, with a drug ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

New York, United States, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ADCs, or antibody-drug conjugates, are chemotherapeutic agents explicitly designed to treat cancer cells. Antibody-drug conjugates ...